Evidence map›Paper›PMID 42267653›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2026

Formulation of Peptide-Based Nanoparticles Using a Microfluidic Device.

Thania Hammoum, Karidia Konate, Yannick Mousli, Sébastien Deshayes, Eric Vivès, Audrey Nsamela, Prisca Boisguérin

Abstract read
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Design of Lipopeptides and dsRNA-Lipopeptide Complexes for Sprayable RNAi-Based Plant Protection.Journal of peptide science : an official publication of the European Peptide Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thania HammoumPhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR9214, Montpellier, France.ORCID https://orcid.org/0009-0004-8362-2426
Karidia KonatePhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR9214, Montpellier, France.ORCID https://orcid.org/0000-0001-5991-5967
Yannick MousliInside Therapeutics, Bègles, France.
Sébastien DeshayesPhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR9214, Montpellier, France.ORCID https://orcid.org/0000-0002-4684-9152
Eric VivèsPhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR9214, Montpellier, France.ORCID https://orcid.org/0000-0001-5391-9641
Audrey NsamelaInside Therapeutics, Bègles, France.
Prisca BoisguérinPhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR9214, Montpellier, France.ORCID https://orcid.org/0000-0002-6955-1340

Funding

Agence Nationale de la Recherche 21-CE18-0022-01Centre national de la recherche scientifique (CNRS)Institut national de la santé et de la recherche médicale (Inserm)Ligue contre le CancerUniversity of Montpellier
6 · The paper itself

Abstract

Peptide-based nanoparticles (PBN) have emerged as a promising alternative to lipid nanoparticles (LNP) for nucleic acid delivery and efficient cellular uptake. In this study, we evaluated the formulation of WRAP5 (W- and R-rich amphipathic peptide 5)-based PBN using a microfluidic device and assessed the impact of key process parameters, flow rate ratio (FRR), total flow rate (TFR), and mixing channel design, on nanoparticle characteristics. Across 72 formulations encapsulating small interfering RNA (siRNA) or plasmid DNA (pDNA), dynamic light scattering revealed consistent mean sizes ranging from 50 to 70 nm, with a low polydispersity index (PdI < 0.22), independent of FRR, TFR, or mixer type. Stability studies demonstrated that siRNA-loaded PBN exhibited moderate size increases during storage at 4°C, whereas pDNA-loaded PBN remained highly stable for up to 70 days. Biological assays confirmed robust activity: WRAP5:siRNA PBN achieved approximately 50% CDK4 silencing in GIST-T1 cells, and WRAP5:pDNA PBN mediated efficient mCHERRY expression in HeLa cells, regardless of formulation method or storage duration. These findings highlight the robustness and scalability of WRAP5-based PBN, contrasting with LNP systems that require stringent control of FRR and TFR, and partially underscore their potential for nucleic acid delivery applications.

Indexed as

Lab-On-A-Chip DevicesNanoparticlesPeptidesDNAHeLa CellsHumansParticle SizePlasmidsRNA, Small InterferingDNAPeptidesRNA, Small InterferingmicrofluidicpDNApeptide‐based nanoparticlesiRNAWRAP5

Identifiers

PMID42267653
PMCPMC13250954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.